Buckley Wealth Management LLC Buys Shares of 5,345 Cencora, Inc. (NYSE:COR)

Buckley Wealth Management LLC bought a new stake in Cencora, Inc. (NYSE:COR) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 5,345 shares of the company’s stock, valued at approximately $1,299,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rise Advisors LLC acquired a new stake in shares of Cencora during the 1st quarter worth approximately $25,000. CVA Family Office LLC acquired a new stake in shares of Cencora during the 1st quarter worth approximately $34,000. Bruce G. Allen Investments LLC acquired a new stake in shares of Cencora during the 1st quarter worth approximately $43,000. Trust Co. of Vermont acquired a new stake in shares of Cencora during the 4th quarter worth approximately $62,000. Finally, Sunbelt Securities Inc. acquired a new stake in shares of Cencora during the 1st quarter worth approximately $67,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity

In other news, COO Robert P. Mauch sold 57,564 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $235.09, for a total transaction of $13,532,720.76. Following the transaction, the chief operating officer now owns 24,412 shares of the company’s stock, valued at $5,739,017.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Cencora news, COO Robert P. Mauch sold 57,564 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $235.09, for a total value of $13,532,720.76. Following the transaction, the chief operating officer now owns 24,412 shares of the company’s stock, valued at $5,739,017.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Dermot Mark Durcan bought 500 shares of the business’s stock in a transaction on Friday, May 24th. The stock was bought at an average cost of $218.58 per share, for a total transaction of $109,290.00. Following the purchase, the director now directly owns 21,876 shares of the company’s stock, valued at approximately $4,781,656.08. The disclosure for this purchase can be found here. Insiders have sold 1,956,675 shares of company stock valued at $422,352,056 over the last 90 days. 15.80% of the stock is owned by company insiders.

Cencora Price Performance

COR traded down $2.50 during trading on Friday, hitting $225.46. The company’s stock had a trading volume of 611,097 shares, compared to its average volume of 1,389,123. The firm’s 50 day moving average price is $229.40 and its two-hundred day moving average price is $227.67. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.41. Cencora, Inc. has a 12 month low of $171.65 and a 12 month high of $246.75. The stock has a market capitalization of $44.97 billion, a price-to-earnings ratio of 24.93, a price-to-earnings-growth ratio of 1.65 and a beta of 0.48.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The firm had revenue of $68.41 billion during the quarter, compared to the consensus estimate of $70.60 billion. During the same quarter in the previous year, the company posted $3.50 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. Sell-side analysts forecast that Cencora, Inc. will post 13.44 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Friday, May 10th were paid a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 0.90%. The ex-dividend date of this dividend was Thursday, May 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on COR shares. SVB Leerink reissued an “outperform” rating and set a $275.00 price objective on shares of Cencora in a report on Thursday. Robert W. Baird boosted their price target on Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Citigroup boosted their price target on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Finally, StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $235.30.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.